Showing results (1171-1180 of 5,058) with videos related to

Sort By:
Pageof 506
Multiple Sclerosis and Related Disorders|December 10, 2020
Are multiple sclerosis patients and their caregivers more anxious and more committed to following the basic preventive measures during the COVID-19 pandemic?Farouk Talaat, Ismail Ramadan, Salma Aly, et al.
Multiple Sclerosis and Related Disorders|January 23, 2022
Validity and reliability of the 3-meter backward walk test in mildly disabled persons with multiple sclerosisFurkan Bilek, Caner Feyzi Demir
Multiple Sclerosis and Related Disorders|May 20, 2022
Validity and reliability of the 3-meter backward walk test in patients with multiple sclerosisZekiye İpek Katirci Kirmaci, Hatice Adiguzel, Suat Erel, et al.
Multiple Sclerosis and Related Disorders|March 28, 2022
Promising role of temelimab in multiple sclerosis treatmentShayan Ali Irfan, Minha Murtaza, Ali Ahmed, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Multiple Sclerosis and Related Disorders|July 11, 2026
Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting SystemAlexandra Balshi, Madelyn Esser, Tamara B Kaplan
Multiple Sclerosis and Related Disorders|July 11, 2026
DIscontinuation of disease-modifying therapies in older adults with multiple sclerosisJieni Li, George J Hutton, Rajender R Aparasu
Multiple Sclerosis and Related Disorders|July 10, 2026
Effectiveness of the adapted Unified Protocol (UP-MSo) in relapsing-remitting multiple sclerosis with overweight/obesity: A pre-registered randomized controlled trial on emotion regulation, eating behavior, and neurological outcomesMaria Consuelo San Martín, Marcos Domic-Siede, Marcela Soto, et al.
Multiple Sclerosis and Related Disorders|July 10, 2026
Evaluating the risk: Hepatitis B virus reactivation in ocrelizumab-treated patients with multiple sclerosis: A single-center experience and review of the literatureBahadır Orkun Ozbay, Uğur Kulu, Aliye Baştuğ, et al.
Multiple Sclerosis and Related Disorders|July 9, 2026
Sex differences in healthcare use before the first multiple sclerosis-related demyelinating eventFarahnaz Amini, Karl Everett, Feng Zhu, et al.
Pageof 506